Marco de Scordilli

@cro.sanita.fvg.it

Medical Oncologist, Department of Medical Oncology
Centro di Riferimento Oncologico (CRO) di Aviano IRCCS

Marco de Scordilli


                        Download Compact PDF  
https://researchid.co/marcodescordilli

EDUCATION

2019-2024 Scuola di Specializzazione in Oncologia Medica - Unversità degli Studi di Udine (votazione: 110/110 e lode)
2011-2017 Laurea Magistrale in Medicina e Chirurgia - Università degli Studi di Trieste (votazione: 110/110 e lode)

RESEARCH, TEACHING, or OTHER INTERESTS

Oncology, Cancer Research, Molecular Medicine
11

Scopus Publications

314

Scholar Citations

8

Scholar h-index

8

Scholar i10-index

Scopus Publications

  • Triplet chemotherapy combined with anti Epidermal Growth Factor Receptor treatment in RAS wild-type colorectal cancer: a network metanalysis
    Paola Di Nardo, Marco de Scordilli, Fabiola Giudici, Debora Basile, Brenno Pastò, Simone Rota, Sara Torresan, Martina Bortolot, Luisa Foltran, Michela Guardascione, Arianna Fumagalli, Claudia Noto, Elena Ongaro, Angela Buonadonna, Fabio Puglisi
    Oncologist, 2026
    Background The optimal first-line treatment for Rat Sarcorma Virus (RAS) wild-type metastatic colorectal cancer remains undetermined. Several studies have compared the efficacy of different first-line regimens, including doublet- or triplet-chemotherapy (CT) alone or in combination with targeted therapies (anti-EGFR/anti-VEGF), without conclusive results. Methods We conducted a systematic review and meta-analysis of phase II/III randomized clinical trials (RCT) comparing triplet-CT+anti-EGFRs with alternative first-line regimens in RAS wild-type patients. Pairwise- and network-meta-analyses were performed to assess overall response rate (ORR). Furthermore, we evaluated PFS and OS with pairwise-metanalyses. Results A total of 1283 patients across seven RCT were included. Four treatment arms were analyzed: Arm A (triplet-CT+anti-EGFR), Arm B (doublet-CT+anti-EGFR), Arm C (triplet al.ne), and Arm D (triplet+anti-VEGF). Arms A, B, and D demonstrated higher ORR compared to Arm C, while no significant differences were found among Arms A, B, and D (OR 1.05, 95% CI 0.73-1.49; P = .804, for Arm B in comparison to Arm A; OR 0.80, 95% CI 0.52-1.25; P = .328, for Arm D in comparison to Arm A). Pairwise-meta-analysis revealed significantly lower ORR for Arm C compared to Arm A (OR 4.23, 95% CI 2.06-8.68, P = .002). P-scores ranked Arm B highest for effectiveness (0.808), followed by Arm A (0.746), then Arm D (0.444) and lastly Arm C (0.002). The pooled Hazard ratios (HRs) for OS demonstrated a superiority for arm A (0.82, 95% CI 0.70-0.97, P = .022) Conclusions Triplet-CT+anti-EGFR demonstrated no clear ORR advantage over other targeted regimens but was superior to triplet-CT alone. Preliminary data indicate a potential OS benefit. Due to increased toxicity, routine use of triplet-CT+anti-EGFR should be carefully evaluated.
  • Vitamins and minerals and their role in cancer: a comprehensive review
    Mattia Garutti, Marco de Scordilli, Martina Alberti, Roberta Mazzeo, Anna Michelotti, Sofia Fagioli, Alessandro Del Conte, Amanda Casirati, Riccardo Caccialanza, Enrico Bartolini, Fabio Puglisi
    Frontiers in Nutrition, 2026
    Cancer remains a leading cause of morbidity and mortality worldwide, influenced by genetic, environmental, and lifestyle factors, including nutrition. This review explores the role of vitamins and minerals in cancer prevention and management, highlighting their critical functions in immune response, DNA synthesis, cellular repair, and antioxidant defense. Vitamins such as A, C, D, E, and the B-complex group, along with minerals like calcium, magnesium, and zinc, are essential for maintaining health and managing oncologic diseases. Cancer patients are often at risk of micronutrient deficiencies due to disease and treatment-related factors; addressing these deficiencies through dietary interventions or supplementation may enhance immune function, reduce treatment-related side effects, and improve overall quality of life. In this review, we comprehensively discuss the biology and physiology of vitamins and minerals with a specific focus on cancer while providing a practical overview of recognizing and managing deficiencies. Furthermore, aligned with the principles of culinary medicine, we have developed a set of recipes for patients and caregivers to manage hypokalemia and hypocalcemia, which are particularly common in clinical practice, aiming to offer useful tools for clinicians and dietitians.
  • Precision oncology in biliary tract cancer: the emerging role of liquid biopsy
    M. de Scordilli, M. Bortolot, S. Torresan, C. Noto, S. Rota, P. Di Nardo, A. Fumagalli, M. Guardascione, E. Ongaro, L. Foltran, F. Puglisi
    ESMO Open, 2025
    Liquid biopsy has already proven effective in aiding diagnosis, risk stratification and treatment personalization in several malignancies, and it could represent a practice-changing tool also in biliary tract cancer, even though clinical applications are currently still limited. It is promising for early diagnosis, especially in high-risk populations, and several studies on circulating free DNA (cfDNA), circulating tumour cells and differential microRNA (miRNA) profiles in this setting are ongoing. Circulating tumour DNA (ctDNA) also appears as a feasible noninvasive biomarker in the curative setting, in detecting minimal residual disease after resection and in monitoring disease recurrence. As of today, it can be particularly valuable in biliary tract cancer for genomic profiling, with a good concordance with tissue samples for most molecular alterations. CtDNA analysis may especially be considered in clinical practice when the tumour tissue is not sufficient for next-generation sequencing, or when urgent therapeutic decisions are needed. Moreover, it offers the possibility of providing a real-time picture to monitor treatment response and dynamically identify resistance mutations, potentially representing a way to optimize treatment strategies.
  • Liquid biopsy in colorectal cancer: Onward and upward
    Sara Torresan, Marco de Scordilli, Martina Bortolot, Paola Di Nardo, Luisa Foltran, Arianna Fumagalli, Michela Guardascione, Elena Ongaro, Fabio Puglisi
    Critical Reviews in Oncology Hematology, 2024
  • Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives
    Marco de Scordilli, Anna Michelotti, Diego Zara, Lorenza Palmero, Martina Alberti, Claudia Noto, Fabiana Totaro, Luisa Foltran, Michela Guardascione, Donatella Iacono, Elena Ongaro, Gianpiero Fasola, Fabio Puglisi
    Critical Reviews in Oncology Hematology, 2023
  • Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials
    Marco de Scordilli, Anna Michelotti, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz
    International Journal of Molecular Sciences, 2022
    The scenario of neoadjuvant and adjuvant settings in non-small cell lung cancer (NSCLC) is rapidly evolving. As already happened for the advanced disease, also early stages have entered the era of precision medicine, with molecular analysis and Programmed death-ligand 1 (PD-L1) evaluation that by now can be considered a routine assessment. New treatment options have been recently approved, with osimertinib now part of clinical practice for Epidermal Growth Factor Receptor mutated (EGFRm) patients, and immune checkpoint inhibitors (ICIs) available after FDA approval both in the adjuvant (atezolizumab) and neoadjuvant (nivolumab) setting. No mature data on overall survival benefits are available yet, though. Several clinical trials with specific-tyrosine kinase inhibitors (TKIs) and ICIs are currently ongoing, both with and without concomitant chemotherapy. As therapeutic strategies are rapidly expanding, quite a few questions remain unsettled, such as the optimal duration of adjuvant targeted therapy or the effective benefit of ICIs in early-stage EGFRm or ALK (Anaplastic Lymphoma Kinase) rearranged patients, or the possibility to individuate high-risk patients after surgical resection assessing minimal residual disease (MRD) by ctDNA evaluation. We hereby report already available literature data and summarize ongoing trials with targeted therapy and immunotherapy in early-stage NSCLC, focusing on practice-changing results and new perspectives for potentially cured patients.
  • NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease
    Anna Michelotti, Marco de Scordilli, Elisa Bertoli, Elisa De Carlo, Alessandro Del Conte, Alessandra Bearz
    International Journal of Molecular Sciences, 2022
    Standard treatment for advanced non-small cell lung cancer (NSCLC) historically consisted of systemic cytotoxic chemotherapy until the early 2000s, when precision medicine led to a revolutionary change in the therapeutic scenario. The identification of oncogenic driver mutations in EGFR, ALK and ROS1 rearrangements identified a subset of patients who largely benefit from targeted agents. However, since the proportion of patients with druggable alterations represents a minority, the discovery of new potential driver mutations is still an urgent clinical need. We provide a comprehensive review of the emerging molecular targets in NSCLC and their applications in the advanced setting.
  • NAFLD-related hepatocarcinoma: The malignant side of metabolic syndrome
    Anna Michelotti, Marco de Scordilli, Lorenza Palmero, Michela Guardascione, Mario Masala, Rossana Roncato, Luisa Foltran, Elena Ongaro, Fabio Puglisi
    Cells, 2021
    Hepatocellular carcinoma (HCC) is the seventh most common cancer worldwide and the second leading cause of cancer-related mortality. HCC typically arises within a cirrhotic liver, but in about 20% of cases occurs in absence of cirrhosis. Among non-cirrhotic risk factors, non-alcoholic fatty liver disease (NAFLD) currently represents the most important emerging cause of HCC in developed countries. It has been estimated that annual incidence of HCC among patients with non-cirrhotic NAFLD is approximately 0.1–1.3 per 1000 patients/year and ranges from 0.5% to 2.6% among patients with non-alcoholic steatohepatitis (NASH) cirrhosis. However, only a few clinical trials enrolling HCC patients actually distinguished NAFLD/NASH-related cases from other non-cirrhotic causes and therefore evidence is still lacking in this subset of patients. This review aims to describe the biology underpinning NAFLD development, to investigate the main molecular pathways involved in its progression to NASH and HCC and to describe how different pathogenetic mechanisms underlying the onset of HCC can have an impact in clinical practice. We hereby also provide an overview of current HCC treatment options, with a particular focus on the available data on NAFLD-related cases in practice-changing clinical trials.
  • Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva
    Michele Bartoletti, Roberta Mazzeo, Marco De Scordilli, Anna Del Fabro, Maria Grazia Vitale, Lucia Bortot, Milena Sabrina Nicoloso, Serena Corsetti, Marta Bonotto, Simona Scalone, Giorgio Giorda, Roberto Sorio, Claudia Andreetta, Maria Luisa Meacci, Rocco De Vivo, Gianpiero Fasola, Francesco Sopracordevole, Fabio Puglisi
    International Journal of Gynecological Cancer, 2020
    BackgroundInvasive vulvar Paget’s disease with over-expression of the human epidermal growth factor receptor 2 (HER2) protein is potentially suitable for targeted therapy, especially in a metastatic setting where no effective treatments are available.MethodsFour consecutive patients with HER2 positive advanced vulvar Paget’s disease, treated with weekly trastuzumab (loading dose 4 mg/kg, then 2 mg/kg) and paclitaxel (80 mg/m2) followed by 3-weekly trastuzumab maintenance (6 mg/kg), are reported.ResultsMedian age and follow-up of patients were 62.5 years (45–74) and 16 months (6-54), respectively. Complete or partial responses were observed in all patients. Median time to response was 3 months (range 2–4), while median duration of response was 10 months (range 2–34). Case 1 presented with pulmonary and lymph nodes involvement. She experienced a radiological complete response after 24 treatment administrations, and a progression-free survival of 36 months. At disease progression, treatment re-challenge achieved partial response. She is currently receiving treatment with trastuzumab–emtansine. Case 2 was a 74-year-old woman who developed pulmonary metastasis after first-line cisplatin treatment. She had a partial response and a progression-free survival of 10 months. Case 3 had inguinal and para-aortic lymphadenopathy in complete response after 18 treatment administrations. She developed brain metastasis while receiving trastuzumab maintenance. Case 4 was treated for locally advanced disease and experienced a subjective benefit with relief in perineal pain and itching. No unexpected treatment-related side effects were reported.ConclusionsAdvanced vulvar Paget’s disease is a rare disorder and no standard treatment is available. In the sub-group of HER2 positive disease, weekly paclitaxel–trastuzumab appears to be active and safe, and may be considered a therapeutic option in these patients.
  • Accuracy of right atrial pressure estimation using a multi-parameter approach derived from inferior vena cava semi-automated edge-tracking echocardiography: a pilot study in patients with cardiovascular disorders
    Stefano Albani, Bruno Pinamonti, Tatiana Giovinazzo, Marco de Scordilli, Enrico Fabris, Davide Stolfo, Andrea Perkan, Caterina Gregorio, Giulia Barbati, Pietro Geri, Marco Confalonieri, Francesco Lo Giudice, Giovanni D. Aquaro, Paolo Pasquero, Massimo Porta, Gianfranco Sinagra, Luca Mesin
    International Journal of Cardiovascular Imaging, 2020
  • Reliability of noninvasive hemodynamic assessment with Doppler echocardiography: comparison with the invasive evaluation
    Marco de Scordilli, Bruno Pinamonti, Stefano Albani, Caterina Gregorio, Giulia Barbati, Chiara Daneluzzi, Renata Korcova, Andrea Perkan, Enrico Fabris, Pietro Geri, Marco Biolo, Francesco Lo Giudice, Marco Confalonieri, Gianfranco Sinagra
    Journal of Cardiovascular Medicine, 2019

RECENT SCHOLAR PUBLICATIONS

  • Triplet CT combined with anti-EGFR treatment in RAS wild-type colorectal cancer; a network metanalysis
    P Di Nardo, M de Scordilli, F Giudici, D Basile, B Pastò, S Rota, ...
    The Oncologist, oyag011 , 2026
    2026
  • 303P Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis
    S Rota, M De Scordilli, F Giudici, E Zottarelli, R Vida, M Zilli, G Bortolus, ...
    Annals of Oncology 36, S119 , 2025
    2025
  • 198P The impact of HLA-E and IFNL4 genes on hepatocellular carcinoma (HCC) development and progression in hepatitis C virus (HCV)-infected patients (VERYMARKERS Study)
    L Foltran, M Guardascione, L Baboci, M De Zorzi, M Trento, V Paduano, ...
    Annals of Oncology 36, S81 , 2025
    2025
  • Triplet therapy with BRAF inhibitor, anti-EGFR agent, and MEK inhibitor in V600E BRAF–mutant colorectal cancer: A meta-analysis.
    M Guardascione, F Giudici, P Di Nardo, S Rota, R Vida, E Ongaro, ...
    Journal of Clinical Oncology 43 (16_suppl), e15558-e15558 , 2025
    2025
  • Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis (NMA).
    E Ongaro, M de Scordilli, F Giudici, S Rota, R Vida, M Zilli, E Zottarelli, ...
    Journal of Clinical Oncology 43 (16_suppl), e16448-e16448 , 2025
    2025
  • Precision oncology in biliary tract cancer: the emerging role of liquid biopsy
    M De Scordilli, M Bortolot, S Torresan, C Noto, S Rota, P Di Nardo, ...
    ESMO open 10 (5), 105079 , 2025
    2025
    Citations: 18
  • Fournier's Gangrene During Lenvatinib Treatment for Hepatocarcinoma
    S Rota, M de Scordilli, R Vida, M Guardascione, P Di Nardo, A Fumagalli, ...
    Cureus 17 (4) , 2025
    2025
  • BOC. 02.6 MULTIMERIN-2 LOSS IMPINGES ON VASCULAR STABILITY FAVORING COLORECTAL CANCER CELL DISSEMINATION
    E Poletto, L Camicia, G Schinello, G Carobolante, N Casagrande, ...
    Digestive and Liver Disease 57, S105 , 2025
    2025
  • Vitamins and minerals and their role in cancer: a comprehensive review
    M Garutti, M de Scordilli, M Alberti, R Mazzeo, A Michelotti, S Fagioli, ...
    Frontiers in Nutrition 12, 1686777 , 2025
    2025
    Citations: 2
  • Safety and efficacy of intensified preoperative management of locally advanced gastrorsophageal junction cancer (INPROVE).
    S Torresan, M Bortolot, M de Scordilli, R Innocente, A Fumagalli, L Foltran, ...
    Journal of Clinical Oncology 42 (16_suppl), e16110-e16110 , 2024
    2024
  • Triplet chemotherapy combined with anti-EGFR treatment in RAS wild-type colon cancer: A network meta-analysis.
    P Di Nardo, F Giudici, D Basile, M De Scordilli, S Torresan, M Bortolot, ...
    Journal of Clinical Oncology 42 (16_suppl), e15592-e15592 , 2024
    2024
  • Chemotherapy with or without surgery for locally advanced or borderline resectable pancreatic ductal adenocarcinoma: A retrospective multicenter international study.
    M Venerito, D Zhang, S Becht, J Schuetz, CD Steup, US Bankstahl, ...
    Journal of Clinical Oncology 42 (16_suppl), e16352-e16352 , 2024
    2024
  • Liquid biopsy in colorectal cancer: Onward and upward
    S Torresan, M de Scordilli, M Bortolot, P Di Nardo, L Foltran, A Fumagalli, ...
    Critical Reviews in Oncology/Hematology 194, 104242 , 2024
    2024
    Citations: 25
  • 2119P The prognostic impact of nutritional assessment and scores in advanced gastric cancer
    S Torresan, M De Scordilli, G Bortolus, M Bortolot, G Zapelloni, R Mazzeo, ...
    Annals of Oncology 34, S1108 , 2023
    2023
  • Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives
    M de Scordilli, A Michelotti, D Zara, L Palmero, M Alberti, C Noto, F Totaro, ...
    Critical Reviews in Oncology/Hematology 186, 104013 , 2023
    2023
    Citations: 8
  • 876P An observational retrospective study on microsatellite instability (MSI) in metastatic melanoma
    G Targato, E Poletto, S Buriolla, M de Scordilli, F Pravisano, G Pascoletti, ...
    Annals of Oncology 33, S949 , 2022
    2022
    Citations: 1
  • 249P A retrospective analysis on capecitabine and vinorelbine combination in metastatic breast cancer: The MARCELLINO study
    M de Scordilli, L Bortot, L Cucciniello, F Totaro, R Mazzeo, M Alberti, ...
    Annals of Oncology 33, S650 , 2022
    2022
  • Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials
    M de Scordilli, A Michelotti, E Bertoli, E De Carlo, A Del Conte, A Bearz
    International journal of molecular sciences 23 (13), 7222 , 2022
    2022
    Citations: 88
  • NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease
    A Michelotti, M de Scordilli, E Bertoli, E De Carlo, A Del Conte, A Bearz
    International journal of molecular sciences 23 (12), 6748 , 2022
    2022
    Citations: 45
  • Breast cancer incidence in patients with BRCA -related advanced ovarian cancer receiving olaparib-based maintenance therapy: A pooled analysis from phase III …
    M Bartoletti, M Montico, R Mazzeo, M De Scordilli, L Musacchio, E Lucia, ...
    Journal of Clinical Oncology 40 (16_suppl), 5566-5566 , 2022
    2022

MOST CITED SCHOLAR PUBLICATIONS

  • Targeted therapy and immunotherapy in early-stage non-small cell lung cancer: current evidence and ongoing trials
    M de Scordilli, A Michelotti, E Bertoli, E De Carlo, A Del Conte, A Bearz
    International journal of molecular sciences 23 (13), 7222 , 2022
    2022
    Citations: 88
  • NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome
    A Michelotti, M de Scordilli, L Palmero, M Guardascione, M Masala, ...
    Cells 10 (8), 2034 , 2021
    2021
    Citations: 50
  • NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease
    A Michelotti, M de Scordilli, E Bertoli, E De Carlo, A Del Conte, A Bearz
    International journal of molecular sciences 23 (12), 6748 , 2022
    2022
    Citations: 45
  • Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva
    M Bartoletti, R Mazzeo, M De Scordilli, A Del Fabro, MG Vitale, L Bortot, ...
    International Journal of Gynecological Cancer 30 (11), 1672-1677 , 2020
    2020
    Citations: 30
  • Liquid biopsy in colorectal cancer: Onward and upward
    S Torresan, M de Scordilli, M Bortolot, P Di Nardo, L Foltran, A Fumagalli, ...
    Critical Reviews in Oncology/Hematology 194, 104242 , 2024
    2024
    Citations: 25
  • Accuracy of right atrial pressure estimation using a multi-parameter approach derived from inferior vena cava semi-automated edge-tracking echocardiography: A pilot study in …
    S Albani, B Pinamonti, T Giovinazzo, M de Scordilli, E Fabris, D Stolfo, ...
    The International Journal of Cardiovascular Imaging 36 (7), 1213-1225 , 2020
    2020
    Citations: 23
  • Precision oncology in biliary tract cancer: the emerging role of liquid biopsy
    M De Scordilli, M Bortolot, S Torresan, C Noto, S Rota, P Di Nardo, ...
    ESMO open 10 (5), 105079 , 2025
    2025
    Citations: 18
  • Reliability of noninvasive hemodynamic assessment with Doppler echocardiography: comparison with the invasive evaluation
    M de Scordilli, B Pinamonti, S Albani, C Gregorio, G Barbati, C Daneluzzi, ...
    Journal of cardiovascular medicine 20 (10), 682-690 , 2019
    2019
    Citations: 18
  • Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives
    M de Scordilli, A Michelotti, D Zara, L Palmero, M Alberti, C Noto, F Totaro, ...
    Critical Reviews in Oncology/Hematology 186, 104013 , 2023
    2023
    Citations: 8
  • LDH as prognostic factor in second line treatment for advanced gastric cancer: The LINE study.
    A Michelotti, M de Scordilli, E Sperti, R Mazzeo, C Corvaja, G Aimar, ...
    Journal of Clinical Oncology 39 (15_suppl), e16102-e16102 , 2021
    2021
    Citations: 4
  • Vitamins and minerals and their role in cancer: a comprehensive review
    M Garutti, M de Scordilli, M Alberti, R Mazzeo, A Michelotti, S Fagioli, ...
    Frontiers in Nutrition 12, 1686777 , 2025
    2025
    Citations: 2
  • 876P An observational retrospective study on microsatellite instability (MSI) in metastatic melanoma
    G Targato, E Poletto, S Buriolla, M de Scordilli, F Pravisano, G Pascoletti, ...
    Annals of Oncology 33, S949 , 2022
    2022
    Citations: 1
  • Prognostic role of macrophage infiltration and monocyte-to-lymphocyte ratio in stage III colon cancer: The MIRROR study.
    D Basile, M Polano, S Buriolla, C Gallois, F Cortiula, C Corvaja, ...
    Journal of Clinical Oncology 38 (15_suppl), e16118-e16118 , 2020
    2020
    Citations: 1
  • Reliability and challenges in non-invasive hemodynamic assessment with doppler echocardiography: comparison with the invasive evaluation: P286
    M De Scordilli, B Pinamonti, S Albani, C Gregorio, G Barbati, C Daneluzzi, ...
    European Heart Journal Cardiovascular Imaging 20, 167 , 2019
    2019
    Citations: 1
  • Triplet CT combined with anti-EGFR treatment in RAS wild-type colorectal cancer; a network metanalysis
    P Di Nardo, M de Scordilli, F Giudici, D Basile, B Pastò, S Rota, ...
    The Oncologist, oyag011 , 2026
    2026
  • 303P Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis
    S Rota, M De Scordilli, F Giudici, E Zottarelli, R Vida, M Zilli, G Bortolus, ...
    Annals of Oncology 36, S119 , 2025
    2025
  • 198P The impact of HLA-E and IFNL4 genes on hepatocellular carcinoma (HCC) development and progression in hepatitis C virus (HCV)-infected patients (VERYMARKERS Study)
    L Foltran, M Guardascione, L Baboci, M De Zorzi, M Trento, V Paduano, ...
    Annals of Oncology 36, S81 , 2025
    2025
  • Triplet therapy with BRAF inhibitor, anti-EGFR agent, and MEK inhibitor in V600E BRAF–mutant colorectal cancer: A meta-analysis.
    M Guardascione, F Giudici, P Di Nardo, S Rota, R Vida, E Ongaro, ...
    Journal of Clinical Oncology 43 (16_suppl), e15558-e15558 , 2025
    2025
  • Neoadjuvant treatments for resectable (RPC) and borderline resectable pancreatic adenocarcinoma (BRPC): A pairwise and network meta-analysis (NMA).
    E Ongaro, M de Scordilli, F Giudici, S Rota, R Vida, M Zilli, E Zottarelli, ...
    Journal of Clinical Oncology 43 (16_suppl), e16448-e16448 , 2025
    2025
  • Fournier's Gangrene During Lenvatinib Treatment for Hepatocarcinoma
    S Rota, M de Scordilli, R Vida, M Guardascione, P Di Nardo, A Fumagalli, ...
    Cureus 17 (4) , 2025
    2025